We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood-Based Assay Detects HER2 Mutations to Guide NSCLC Treatment

By LabMedica International staff writers
Posted on 15 Jun 2026

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and a subset of patients harbor HER2 (ERBB2) mutations that may be addressed with precision therapies. More...

These HER2‑mutant tumors are aggressive and have been associated with a poor prognosis. Because tissue sampling can be difficult in advanced disease, blood-based testing offers a faster, less invasive alternative. A newly approved companion diagnostic now uses a liquid biopsy to identify adults with HER2‑mutant advanced NSCLC who are eligible for a targeted therapy.

Guardant Health’s Guardant360 CDx has received U.S. Food and Drug Administration (FDA) approval as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets), recognized as the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment option. The approval enables the blood-based assay to identify patients with HER2 tyrosine kinase domain activating mutations who may be eligible for treatment with HERNEXEOS. The test expands access to biomarker-driven therapy selection using a simple blood draw.

Guardant360 CDx is a liquid biopsy that analyzes circulating tumor DNA from a blood sample, detecting tumor-derived alterations in circulating cell-free DNA. By providing comprehensive genomic profiling across multiple tumor types and biomarkers, the assay helps clinicians match patients to appropriate targeted therapies and clinical trials. The approach can be advantageous when tissue biopsy is infeasible or delayed in advanced disease.

HERNEXEOS is indicated for adult patients with unresectable or metastatic non-squamous NSCLC whose tumors harbor HER2 tyrosine kinase domain activating mutations, as detected by an FDA‑authorized test. The indication was granted under accelerated approval based on objective response rate and duration of response, with continued approval contingent upon confirmatory evidence of clinical benefit. This latest FDA decision represents the 27th companion diagnostic indication for Guardant360 CDx across multiple tumor types globally, and the test is broadly covered by Medicare and commercial payers representing more than 300 million covered lives.

Guardant360 CDx was the first FDA‑approved liquid biopsy for comprehensive genomic profiling. The assay detects multiple genomic alterations across all solid tumors. It is also approved as a companion diagnostic for therapies in NSCLC, breast cancer, and colorectal cancer.

“This approval highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx to ensuring more patients can be matched to the right therapy at the right time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant360 CDx has been at the forefront of enabling comprehensive genomic profiling through a simple blood draw, helping clinicians identify actionable mutations in genes such as HER2 with speed and accuracy.”

Related Links
Guardant Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.